Land: Malta
Språk: engelsk
Kilde: Medicines Authority
PANCURONIUM BROMIDE
Hospira UK Limited
M03AC01
PANCURONIUM BROMIDE
SOLUTION FOR INJECTION
PANCURONIUM BROMIDE 2 mg/ml
POM
MUSCLE RELAXANTS
Authorised
2006-12-28
Q63027 Artworker I have checked that this artwork conforms with the information received. Signature: Date: / / Proofer I have given this artwork a final check and it conforms with the information received. Signature: Date: / / Administrator I have checked the paperwork and it conforms with the artwork and information received. Signature: Date: / / Regulatory I have checked this artwork against the registered text including spelling, layout, size, colours, registration numbers and scientific equations, the name and address and trademarks. Also for any possible changes to related items. This artwork is in conformance with the Marketing Authorisation and can now proceed to the printing stage. I have also signed the Supplier’s Specification and where necessary a Change Request form. Signature: Date: / / QA EMEA I have checked the paperwork and it conforms with the artwork and information received. Signature: Date: / / N.B.: Regulatory approval on text and layout. Production requirements may be added via manufacturing site. Copyright in this drawing, design and specification or artwork vests in Hospira UK Limited and must not be copied or reproduced without the express prior permission of Hospira UK Limited. Any unauthorised act in relation to this work will result in both civil and criminal liability. Copyright © Hospira UK Limited October 2007 HOSPIRA UK LIMITED - Draft artwork Request Number: AM1323 Country: UK Product Code(s): 08971D-GB Artworker: KN Version Number: 2 Drafted: 25/04/08 Specification OI Template: BPS-0059/2 Dimensions: 148 x 420 mm Template type: In-licence Leaflet Container: Ampoule Supplier: Hameln Stock: N/A Folded dimensions: N/A Printed both sides: Yes Les hele dokumentet
Page 1 of 9 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Pancuronium Bromide 2 mg/ml Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml contains 2 mg of pancuronium bromide. Each 2 ml ampoule contains 4 mg of pancuronium bromide. For excipients, see 6.1. 3. PHARMACEUTICAL FORM Solution for injection 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS The active substance of pancuronium bromide is an amino steroid which effectively blocks transmission of motor nerve impulses to the striated muscle receptors. It is a non-depolarising neuromuscular blocking agent with a long duration of action and is used in the following indications: 1. As an adjuvant in surgical anaesthesia to obtain relaxation of skeletal muscles in a wide range of surgical procedures. 2. Use in intensive care as a non-depolarising neuromuscular blocker for the treatment of various pathologies eg intractable status asthmaticus and tetanus. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION Pancuronium should be administered intravenously. It is not recommended to be given by infusion. The dosage should be individualised as there is a wide variation in individual response to muscle relaxants. When determining the dose, the method of anaesthesia, expected duration of surgery, potential interaction with other drugs that are administered before and during anaesthesia and the condition of the patient should be taken into account. The use of a peripheral nerve stimulator is recommended for monitoring the neuromuscular block and recovery. Page 2 of 9 ADULT: Les hele dokumentet